This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME. UNITY Biotechnology, Inc. is set to host an in-person ...

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024. Thierry Bordet, CSO of PulseSight Therapeutics, said spoke about this ...

Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology to Sierra Family Health Center (SFHC) and Western Sierra Medical Clinic (WSMC). ASI has integrated a retinal ...